Featured Research

from universities, journals, and other organizations

Gene May Bias Amygdala Response To Frightful Faces

Date:
July 22, 2002
Source:
NIH/National Institute Of Mental Health
Summary:
The amygdala, the brain structure known as the hub of fear, responds differently to pictures of scary faces, depending on which version of a gene one has inherited, report National Institute of Mental Health scientists.

The amygdala, the brain structure known as the hub of fear, responds differently to pictures of scary faces, depending on which version of a gene one has inherited, report National Institute of Mental Health scientists.

Functional Magnetic Resonance Imaging (fMRI) scans revealed that subjects who inherited one or two copies of the short variant of the human serotonin transporter gene experienced greater activation of the amygdala when shown the pictures than those with two copies of the long variant of the gene. The gene's effect on the amygdala's response to emotional stimuli may help shape a dimension of temperament, suggest Drs. Ahmad Hariri and Daniel Weinberger, NIMH, and colleagues, in the July 19, 2002 Science.

"How biologically reactive we are to a signal of danger, which is partly heritable, can place us at risk for an anxiety disorder or it may be an adaptive, positive attribute, such as increased vigilance, depending on the circumstances," explained Weinberger. "Anxiety is a complex experience not caused by any one gene or environmental factor. By showing how a variation in a gene exerts its influence on the brain's center for fear processing, this finding may lend credence to earlier reports linking the short gene variant to slightly higher levels of anxiety. It provides potential insight into one factor that contributes to the way people experience emotion."

Each of us inherits two copies of the transporter gene for the chemical messenger serotonin , one from each parent. It codes for the protein in neurons that recycles secreted serotonin from the synapse. Serotonin reuptake inhibitors (SSRIs), the most widely prescribed medications for anxiety and depression, act by blocking the transporter. The two common genetic variations occur in a region of the gene that acts like a dimmer switch, controlling the level of the gene's turning on and off. This leads to transporter proteins that function somewhat differently. The short variant makes less protein, resulting in increased levels of serotonin in the synapse and more binding of the neurotransmitter to receptors on connecting neurons.

In the fMRI paradigm, developed by Hariri and colleagues, 28 subjects performed a facial emotion-matching task on a computer screen while their brain activity was scanned. They matched one of two faces that appeared at the bottom of the screen having the same emotion – angry or afraid – expressed on a face at the top of the screen. This task is known to activate the amygdala, a small almond-shaped structure deep in the brain that processes fearful stimuli. Those with one or two copies of the short gene variant showed greater activation of the amygdala on the right side of the brain, which is specialized for processing faces. When the subjects performed a thinking task that did not involve emotional processing and the amygdala, no effects of the gene variants were seen.

The current study did not detect any differences in anxiety traits traceable to the serotonin transporter gene variants, perhaps because the sample was too small. Earlier studies by Dennis Murphy, M.D., NIMH, and colleagues, found that the variants accounted for three to four percent of the variance in anxiety traits. A few other studies using behavioral measurements have since turned up similar results, but the research has remained controversial due to the relatively small effect sizes.

"The fMRI study takes the genetic analysis forward to the level of neurobiology, closing one more link in the chain of causality between a functional difference in a gene and a complex behavior," noted David Goldman, M.D., National Institute on Alcohol Abuse and Alcoholism (NIAAA), one of the study authors.

Differences seen in adult subjects may be rooted in early critical periods in which the gene variants may affect the course of emotional development and temperament, the journal article suggests.

Also participating in the research were Drs. Venkata Mattay, Alessandro Tessitore, Bhaskar Kolachana, Francesco Fera, and Michael Egan, NIMH.

NIMH and NIAAA are part of the National Institutes of Health (NIH), the Federal Government's primary agency for biomedical and behavioral research. NIH is a component of the U.S. Department of Health and Human Services.


Story Source:

The above story is based on materials provided by NIH/National Institute Of Mental Health. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute Of Mental Health. "Gene May Bias Amygdala Response To Frightful Faces." ScienceDaily. ScienceDaily, 22 July 2002. <www.sciencedaily.com/releases/2002/07/020722073438.htm>.
NIH/National Institute Of Mental Health. (2002, July 22). Gene May Bias Amygdala Response To Frightful Faces. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2002/07/020722073438.htm
NIH/National Institute Of Mental Health. "Gene May Bias Amygdala Response To Frightful Faces." ScienceDaily. www.sciencedaily.com/releases/2002/07/020722073438.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins